February 6, 2013
Boston Business Journal
Catabasis rakes in $8M fundraise
Catabasis Pharmaceuticals Inc. saw positive results of its Phase 1 study of its lead program, CAT-1004, which is focused on inflammatory diseases.
The three-part study was to test both the safety and tolerability of the compound formed by the omega-3 fatty acid and salicylate. In preclinical studies, CAT-1004 has been shown to activate endogenous anti-inflammatory pathways to treat inflammation. Treatment with CAT-1004 resulted in inhibition of NF-kB pathway, which in muscle satellite cells has been shown to have a positive effect in Duchenne muscular dystrophy (DMD). DMD is a form of muscular dystrophy which occurs in about 1 out of every 3,600 male infants. The disorder - for which there is no cure - is caused by the dystrophin gene located on the human X chromosome.
“In terms of DMD, our interest in that has been to target inflammation. It’s not curative, but you can keep boys out of wheelchairs longer,” CEO and Co-founder Jill Milne told Mass High Tech.
“This is very encouraging preclinical data,” added Michael Jirousek, co-founder and chief scientific officer of Catabasis. “We’ve seen reduction in degeneration in muscle. With our technology we are able to deliver the compound in a safe way.”
With the number of companies working on treatments for DMD, there is opportunity for collaboration, according to Catabasis.
To read the full article, visit: http://www.bizjournals.com/boston/blog/bioflash/2013/02/catabasis-sees-positive-phase-1-data.html